CA3132823A1 - Systems and methods for drug-agnostic patient-specific dosing regimens - Google Patents
Systems and methods for drug-agnostic patient-specific dosing regimens Download PDFInfo
- Publication number
- CA3132823A1 CA3132823A1 CA3132823A CA3132823A CA3132823A1 CA 3132823 A1 CA3132823 A1 CA 3132823A1 CA 3132823 A CA3132823 A CA 3132823A CA 3132823 A CA3132823 A CA 3132823A CA 3132823 A1 CA3132823 A1 CA 3132823A1
- Authority
- CA
- Canada
- Prior art keywords
- patient
- drug
- drugs
- dosing regimen
- model
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 136
- 239000003814 drug Substances 0.000 claims abstract description 717
- 229940079593 drug Drugs 0.000 claims abstract description 714
- 230000004044 response Effects 0.000 claims description 187
- 238000013178 mathematical model Methods 0.000 claims description 81
- 230000003285 pharmacodynamic effect Effects 0.000 claims description 74
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 67
- 201000010099 disease Diseases 0.000 claims description 66
- 238000011282 treatment Methods 0.000 claims description 62
- 238000005259 measurement Methods 0.000 claims description 46
- 238000005094 computer simulation Methods 0.000 claims description 43
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 24
- 230000000694 effects Effects 0.000 claims description 24
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 23
- 102100032752 C-reactive protein Human genes 0.000 claims description 23
- 229960000598 infliximab Drugs 0.000 claims description 23
- 201000004681 Psoriasis Diseases 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 230000006399 behavior Effects 0.000 claims description 13
- 238000002560 therapeutic procedure Methods 0.000 claims description 13
- 229960002964 adalimumab Drugs 0.000 claims description 12
- 108010088751 Albumins Proteins 0.000 claims description 11
- 102000009027 Albumins Human genes 0.000 claims description 11
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 11
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 11
- 239000000090 biomarker Substances 0.000 claims description 11
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 11
- 208000006673 asthma Diseases 0.000 claims description 10
- 230000036772 blood pressure Effects 0.000 claims description 10
- 230000000052 comparative effect Effects 0.000 claims description 10
- 208000027866 inflammatory disease Diseases 0.000 claims description 10
- 238000009533 lab test Methods 0.000 claims description 10
- 206010061218 Inflammation Diseases 0.000 claims description 9
- 230000007423 decrease Effects 0.000 claims description 9
- 238000005534 hematocrit Methods 0.000 claims description 9
- 230000004054 inflammatory process Effects 0.000 claims description 9
- 230000010534 mechanism of action Effects 0.000 claims description 9
- 201000006417 multiple sclerosis Diseases 0.000 claims description 9
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 8
- 238000004458 analytical method Methods 0.000 claims description 8
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 229940127089 cytotoxic agent Drugs 0.000 claims description 8
- 230000009266 disease activity Effects 0.000 claims description 8
- 238000007920 subcutaneous administration Methods 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 238000001990 intravenous administration Methods 0.000 claims description 7
- 239000003550 marker Substances 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 claims description 6
- 230000015556 catabolic process Effects 0.000 claims description 6
- 238000006731 degradation reaction Methods 0.000 claims description 6
- 238000007918 intramuscular administration Methods 0.000 claims description 6
- 238000007913 intrathecal administration Methods 0.000 claims description 6
- 238000002663 nebulization Methods 0.000 claims description 6
- 238000003786 synthesis reaction Methods 0.000 claims description 6
- 238000010207 Bayesian analysis Methods 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 238000002641 enzyme replacement therapy Methods 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 230000006870 function Effects 0.000 description 26
- 230000008569 process Effects 0.000 description 22
- 238000004891 communication Methods 0.000 description 21
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000008030 elimination Effects 0.000 description 10
- 238000003379 elimination reaction Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 238000011161 development Methods 0.000 description 8
- 239000002547 new drug Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 238000004088 simulation Methods 0.000 description 8
- 238000013500 data storage Methods 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 206010009900 Colitis ulcerative Diseases 0.000 description 6
- 208000011231 Crohn disease Diseases 0.000 description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 239000006187 pill Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000004797 therapeutic response Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000007620 mathematical function Methods 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 229960004914 vedolizumab Drugs 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 229960000074 biopharmaceutical Drugs 0.000 description 4
- 238000001815 biotherapy Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000004590 computer program Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 101000664681 Homo sapiens Peroxisomal sarcosine oxidase Proteins 0.000 description 3
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 description 3
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000013398 bayesian method Methods 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000044800 human PIPOX Human genes 0.000 description 3
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 229940121354 immunomodulator Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000020925 Bipolar disease Diseases 0.000 description 2
- 108010008165 Etanercept Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000010405 clearance mechanism Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 229960000403 etanercept Drugs 0.000 description 2
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 2
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229950010864 guselkumab Drugs 0.000 description 2
- 230000008938 immune dysregulation Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 229950007943 risankizumab Drugs 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 229950006348 sarilumab Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 102100023006 Basic leucine zipper transcriptional factor ATF-like 2 Human genes 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 101000903615 Homo sapiens Basic leucine zipper transcriptional factor ATF-like 2 Proteins 0.000 description 1
- 101001109465 Homo sapiens NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 description 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 244000078534 Vaccinium myrtillus Species 0.000 description 1
- 229960003697 abatacept Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940119059 actemra Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229950000321 benralizumab Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000021029 blackberry Nutrition 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229960001838 canakinumab Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 229960003115 certolizumab pegol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- -1 chemotherapy Substances 0.000 description 1
- 229940090100 cimzia Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229940010466 cosentyx Drugs 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229950003468 dupilumab Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 102000056368 human NLRP3 Human genes 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229960005435 ixekizumab Drugs 0.000 description 1
- 229940047834 lemtrada Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960005108 mepolizumab Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 229940109690 nucala Drugs 0.000 description 1
- 229950005751 ocrelizumab Drugs 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229940035567 orencia Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001690 polydopamine Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 229960003254 reslizumab Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 229960004540 secukinumab Drugs 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 229940068638 simponi Drugs 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 229940071598 stelara Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940060681 taltz Drugs 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
- 229940079023 tysabri Drugs 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229940099073 xolair Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Data Mining & Analysis (AREA)
- Biomedical Technology (AREA)
- Databases & Information Systems (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962815825P | 2019-03-08 | 2019-03-08 | |
US62/815,825 | 2019-03-08 | ||
US16/391,950 US20190326002A1 (en) | 2018-04-23 | 2019-04-23 | Systems and methods for modifying adaptive dosing regimens |
USPCT/US2019/028750 | 2019-04-23 | ||
US16/391,950 | 2019-04-23 | ||
PCT/US2019/028750 WO2019209845A1 (en) | 2018-04-23 | 2019-04-23 | Systems and methods for modifying adaptive dosing regimens |
PCT/US2020/021742 WO2020185699A1 (en) | 2019-03-08 | 2020-03-09 | Systems and methods for drug-agnostic patient-specific dosing regimens |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3132823A1 true CA3132823A1 (en) | 2020-09-17 |
Family
ID=72426742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3132823A Pending CA3132823A1 (en) | 2019-03-08 | 2020-03-09 | Systems and methods for drug-agnostic patient-specific dosing regimens |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP3935639A1 (ko) |
JP (1) | JP2022524083A (ko) |
KR (1) | KR20220002884A (ko) |
AU (1) | AU2020239014A1 (ko) |
CA (1) | CA3132823A1 (ko) |
IL (1) | IL286145A (ko) |
SG (1) | SG11202109704UA (ko) |
WO (1) | WO2020185699A1 (ko) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220143460A1 (en) * | 2020-11-10 | 2022-05-12 | Willowview Consulting, Llc | Method and system for dynamically transforming user health and exercise-related data into visual, audio, textual, and physical data representations |
US20220199266A1 (en) * | 2020-12-10 | 2022-06-23 | DataRobot, Inc. | Systems and methods for using machine learning with epidemiological modeling |
CN113643785B (zh) * | 2021-07-22 | 2023-09-01 | 海南大学 | 基于dikw图谱的疫苗接种浓度确认方法 |
CN116453669B (zh) * | 2023-06-14 | 2023-08-25 | 武汉大学中南医院 | 一种基于大数据的护理预测方法及装置 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2887072C (en) | 2012-10-05 | 2024-04-16 | Baysient LLC | System and method for providing patient-specific dosing as a function of mathematical models |
US11501863B2 (en) | 2015-04-09 | 2022-11-15 | Diane R. MOULD | Systems and methods for patient-specific dosing |
-
2020
- 2020-03-09 EP EP20714457.7A patent/EP3935639A1/en active Pending
- 2020-03-09 SG SG11202109704U patent/SG11202109704UA/en unknown
- 2020-03-09 KR KR1020217032413A patent/KR20220002884A/ko unknown
- 2020-03-09 CA CA3132823A patent/CA3132823A1/en active Pending
- 2020-03-09 JP JP2021553012A patent/JP2022524083A/ja active Pending
- 2020-03-09 AU AU2020239014A patent/AU2020239014A1/en active Pending
- 2020-03-09 WO PCT/US2020/021742 patent/WO2020185699A1/en unknown
-
2021
- 2021-09-05 IL IL286145A patent/IL286145A/en unknown
Also Published As
Publication number | Publication date |
---|---|
SG11202109704UA (en) | 2021-10-28 |
IL286145A (en) | 2021-10-31 |
KR20220002884A (ko) | 2022-01-07 |
JP2022524083A (ja) | 2022-04-27 |
EP3935639A1 (en) | 2022-01-12 |
AU2020239014A1 (en) | 2021-10-07 |
WO2020185699A1 (en) | 2020-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200321096A1 (en) | Systems and methods for drug-agnostic patient-specific dosing regimens | |
US20190326002A1 (en) | Systems and methods for modifying adaptive dosing regimens | |
US11734593B2 (en) | Bayesian causal relationship network models for healthcare diagnosis and treatment based on patient data | |
US20230178203A1 (en) | Systems and methods for patient-specific dosing | |
CA3132823A1 (en) | Systems and methods for drug-agnostic patient-specific dosing regimens | |
Johnson et al. | Real-world adherence and persistence to oral disease-modifying therapies in multiple sclerosis patients over 1 year | |
JP5970449B2 (ja) | 処置成果を予測するためのコンピュータベースシステム | |
Chen et al. | OrderRex: clinical order decision support and outcome predictions by data-mining electronic medical records | |
US10262112B2 (en) | Prescription decision support system and method using comprehensive multiplex drug monitoring | |
US20220383991A1 (en) | Systems and methods for monoclonal antibody nomograms | |
Taylor et al. | Determinants of treatment eligibility in veterans with hepatitis C viral infection | |
Rattsev et al. | Incorporation of emergent symptoms and genetic covariates improves prediction of aromatase inhibitor therapy discontinuation | |
WO2024097993A1 (en) | Machine learning-based risk stratification and management of non-alcoholic fatty liver disease | |
Fisher | Comparative persistence of tumor necrosis factor alpha antagonists in patients with rheumatoid arthritis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20240311 |